How have AIMD and APRE total returns compared?

Over the past 5 years, AIMD delivered -58.50% and APRE delivered -63.30% annualized total return. Past performance doesn't predict future results.

Ainos, Inc. (AIMD) vs Aprea Therapeutics, Inc. (APRE)

A side-by-side comparison of Ainos, Inc. and Aprea Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AIMD

Ainos, Inc.

$10M

$1.32HealthcareDelayed quote: Oct 6, 2026, 2:59 PM EDT

APRE

Aprea Therapeutics, Inc.

$8M

$0.64HealthcareDelayed quote: Oct 6, 2026, 2:58 PM EDT

Total return — AIMD vs APRE

growth of $100 · dividends reinvested · last 6y

AIMD -97.7% (-46.6%/yr)APRE -99.3% (-56.7%/yr)AIMD compounded faster over this window

AIMD APRE

AIMD vs APRE: by the numbers

•AIMD is the larger company ($10M vs $8M market cap).
•Both run net losses; APRE's is the smaller (0.00% vs -106283.32% net margin).

Metrics side by side

Valuation

Metric	AIMD	APRE
P/S ratio	713.39	N/A
P/B ratio	2.95	0.20

Profitability

Metric	AIMD	APRE
Gross margin	-3767.20%	0.00%
Operating margin	-11268.32%	0.00%
Net margin	-106283.32%	0.00%
ROE	-440.15%	-31.99%
ROIC	-80.51%	-33.73%

Growth (annualized)

Metric	AIMD	APRE
Revenue CAGR (5Y)	49.62%	N/A
Total return CAGR (5Y)	-58.50%	-63.30%

Frequently asked

How have AIMD and APRE total returns compared?: Over the past 5 years, AIMD delivered -58.50% and APRE delivered -63.30% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AIMD analysis Full APRE analysis Interactive comparison tool

Dig into the metrics

Ainos ROE Aprea Therapeutics ROE Ainos operating margin Aprea Therapeutics operating margin Ainos revenue growth Aprea Therapeutics revenue growth Ainos free cash flow Aprea Therapeutics free cash flow

Ainos & Aprea Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.